Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Post-hoc Analysis from a Long-term Clinical Study – JCAD | The Journal of Clinical
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial* - Augustin -
SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps)
Emerging Insights in the Treatment of Psoriasis and Psoriatic Arthritis - European Medical Journal
SIMPONI ARIA® Psoriatic Arthritis Efficacy: PASI Response | HCP
Novartis' plaque psoriasis drug keeps skin clear 4 years post treatment
Plaque Psoriasis Efficacy | Enbrel® (etanercept)
Plaque Psoriasis Efficacy | Enbrel® (etanercept)
Secukinumab 2‐weekly vs. 4‐weekly dosing in patients with plaque‐type psoriasis: results from the randomized GAIN study* - Reich - 2021 - British Journal of Dermatology - Wiley Online Library
Evolution of psoriasis endpoint use - IQVIA
SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps)
Time to Raise the Bar to Psoriasis Area Severity Index 90 and 100 - JDDonline - Journal of Drugs in Dermatology
Patients' and Physicians' Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare) | HTML | Acta Dermato-Venereologica
NNTs show once-unimaginable psoriasis outcomes now readily attainable | MDedge Rheumatology
Plaque Psoriasis Skin Clearance | COSENTYX® (secukinumab)
PASI 75, PASI 90, and PASI 100 response at week 12 for patients... | Download Scientific Diagram
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis - ScienceDirect
Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan | PLOS ONE
VOYAGE 1: Moderate to Severe PsO | TREMFYA® (guselkumab) HCP
New Novartis data shows Cosentyx™ is significantly superior to Stelara® and clears skin (PASI 90) in nearly 80% of psoriasis patients | Novartis
PASI 75, PASI 90, and PASI 100 response by baseline psoriasis severity... | Download Scientific Diagram
Access to Biologics in Argentina: Rethinking Time to PASI 90 | International Psoriasis Council
STELARA® (ustekinumab) Efficacy Data: Moderate to Severe Plaque Psoriasis
PASI 90 response over time in ECLIPSE study (2). The efficacy of both... | Download Scientific Diagram
Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial - ScienceDirect
Tildrakizumab in Patients with Moderate-to-Severe Psoriasis: Post-Hoc Analyses on Efficacy, Time to Relapse, Long-Term Safety in Elderly Population and Predictability From The reSURFACE 1 and reSURFACE 2 Phase III Clinical Trials -
Skin Clearance | Efficacy | RINVOQ® (upadacitinib)
